Abstract
Introduction
The cytoprotective properties of certain potassium channel openers (KCOs), such as diazoxide or pinacidil, have been extensively observed and studied under conditions of ischemia and reperfusion [1] . After the discovery that potassium channels are present also in the inner mitochondrial membrane and finding that they are potential targets for KCOs, the influence of KCOs on mitochondrial function has received considerable attention [2] [3] [4] . In the inner mitochondrial membrane several potassium channels have been identified including the ATP-236 regulated potassium channel (mitoK ATP ) [5] , large conductance calcium-activated potassium channel (mitoBK Ca ) [6] and voltage-dependent potassium channel (mitoKv1.3) [7] . At present, it is broadly accepted that pharmacological preconditioning with KCOs leads to cytoprotection through the activation of potassium channels localised in the mitochondria [8, 9] .
Increased permeability of the inner mitochondrial membrane to potassium ions can decrease the mitochondrial membrane potential, increase the respiration rate and induce matrix swelling. Such effects are observed upon KCOs administration [10, 11] . Still, the link between the modulation of mitochondrial function by KCOs and cytoprotection remains unclear. It has been proposed that this phenomenon is a consequence of matrix volume modulation [12] , diminished calcium uptake into the mitochondria due to decreased membrane potential [13, 14] or mild stimulation of mitochondrial ROS production leading to the activation of pro-survival signalling pathways [15, 16] . However, the assumption that pharmacological preconditioning with KCOs arises from the opening of mitochondrial potassium channels has been questioned due to the doubtful specificity of available potassium channel modulators [17] . Diazoxide, which has been used in the majority of studies concerning KCOs-mediated cytoprotection, has also channel-independent actions: it has been shown to inhibit succinate dehydrogenase (SDH) [18, 19] and to have protonophoric properties [20] . Thus, it has been suggested that diazoxide-mediated cardioprotection can be attributed to these non-specific activities rather than to effects on mitochondrial potassium fluxes.
BMS-191095 [(3R)-trans-4-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)dimethyl-2H-1-benzopyran-6-
carbonitril monohydrochloride] is a mitoK ATP opener that has been reported to be cytoprotective in the conditions of ischemia-reperfusion in cardiac [21] , brain [22] and skeletal muscle tissue [23] . The influence of this drug on cardiac mitoK ATP channels was confirmed with functional studies [24] , as well as with single channel recordings [25] . Moreover, BMS-191095 is devoid of non-specific activities described for diazoxide such as increased mitochondrial ROS generation attributed to SDH inhibition [26, 27] and vasodilatory activity resulting from activation of plasmalemmal K ATP channels in vascular smooth muscle cells [21] . Therefore, the cytoprotective properties of BMS-191095 strengthen the evidence that the beneficial effects of potassium channel openers on cell survival result from the modulation of potassium flux across the inner mitochondrial membrane. However, BMS-191095 has been until now much less studied than diazoxide and its high selectivity toward mitochondrial potassium channels still needs to be confirmed.
The aim of this study was to compare the cytoprotective potential of BMS-191095 under the conditions of oxidative stress and elevated intracellular calcium levels and to delineate the mechanism underlying the potential cytoprotective action of this potassium channel opener. As a model we used C2C12 myoblasts, in which cell injury was induced by treatment with hydrogen peroxide or with calcium ionophore A23187. The results suggest a link between BMS-191095-mediated cytoprotection and the beneficial effects of the drug on the maintenance of intracellular calcium homeostasis under stress conditions.
Materials and Methods

Reagents
Most of the chemicals used in this study were purchased from Sigma, with the exception of calpain inhibitors PD 150606 and N-acetylleucylleucylnorleucinal -ALLN (Calbiochem), fluo-3-AM (Molecular Probes), foetal bovine serum and L-glutamine (Gibco). BMS-191095 was obtained from Bristol-Myers-Squibb. Stock solutions of BMS-191095 (10 mM), PD150606 (20 mM), ALLN (20 mM), Z-vad-FMK (20 mM), cyclosporine A (1 mM) and A23187 (2 mM) were prepared in DMSO. Sodium 5-hydroxydecanoate was dissolved in water. Directly before the experiments, appropriate dilutions of the chemicals were prepared in the medium used in the particular measurement (HBSS-HEPES or DMEM) and used for cell treatment.
Cell culture conditions C2C12 murine myoblasts were obtained from ECACC. Cells were cultured at 37 °C in a humidified atmosphere with 5% CO 2 , in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 20% foetal bovine serum (FBS), 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. Cell injury tests and calpain activity assays were performed in culture medium containing 0.1% FBS.
Determination of cell injury levels
Cells grown in 96-well plates (at about 6 x 10 3 cells per well) were treated for 6 h with damaging agents. Then, cell survival was estimated using the lactate dehydrogenase (LDH) release test or the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] reduction assay.
LDH release was measured using the Cytotoxicity Detection Kit (Roche Molecular Biochemicals). After incubation with tested chemicals, cell medium was collected and cell debris was removed by centrifugation. In parallel, 0.1% Triton X-100 was added to each well to lyse attached cells. LDH activity in cell lysates and in the incubation medium was measured colorimetrically according to the instructions provided by the Malinska/Kulawiak/Wrzosek/Kunz/Szewczyk Cell Physiol Biochem 2010;26:235-246 producer. The amount of LDH released from the cells was calculated as follows:
% of LDH release = (LDH medium / LDH total ) × 100%, where LDH medium -LDH activity detected in incubation medium, LDH total -sum of the LDH activities detected in incubation medium and in cell lysates.
To test cellular survival using the MTT reduction assay, cells were chemically treated and the cell medium was discarded. To each well, 50 µl of DMEM containing 0.5 mg/ml of MTT was added. After 2 h of incubation, 50 µl of lysis buffer (20% sodium dodecylsulfate, 50% N,N-dimethylformamide, 2% acetic acid and 25 mM HCl) was added to each well and the plates were kept overnight at 37°C. The amount of MTT formazan formed was determined by absorbance measurement at 570 nm. As a reference wavelength, 650 nm was used. The results were normalised against values measured in untreated controls in each of the experiments.
Calpain activity assays
Calpain activity in C2C12 cells was measured with the Calpain-Glo Protease Assay (Promega). The assay detects the summaric activity of calpains, without distinguisning between the particular isoforms. Cells grown in 96-well plates were treated for 2 h with tested substances in the presence of 20 µM of the proluminescent calpain substrate succinyl-LLVYaminoluciferin. Then cells were lysed by adding Triton X-100 to a final concentration of 1%. To prevent further cleavage of the proluminescent substrate, 50 µM ALLN, an inhibitor of calpain and proteasome, was also added. The lysates were mixed 1:1 with the luciferin detection reagent provided by the manufacturer and after 10 minutes of incubation the amount of the cleaved substrate was assessed by luminescence measurements. The results were normalised against calpain activity detected in untreated controls in corresponding experiment.
The direct effect of BMS-191095 and PD 150606 on the activity of purified µ-calpain from porcine pancreas and on the activity of calpains in C2C12 cells was investigated using the fluorescent probe N-succinyl-LLVY-7-amido-4-methylcoumarin (succ-LLVY-AMC). Calpain-mediated cleavage of the probe was monitored by measuring the increase in fluorescence at λ ex = 380 nm and λ em = 460 nm in presence of 10 µM of succ-LLVY-AMC. The measurement buffer consisted of 120 mM KCl, 5 mM KH 2 PO 4 , 0.5 mM MgCl 2 , 10 mM HEPES and 5 mM EGTA, pH 7.3. For measurement of calpain activity in C2C12 myoblasts, around 0.3 million cells were detached by trypsinisation and suspended in PBS. The suspension was divided into three equal samples that were incubated for 15 minutes with, respectively, 30 µM BMS-191095, 100 µM PD 150606 or in PBS alone (control sample). Afterwards, the cells were permeabilised with digitonin (40 µg/ml) and calpain activity was measured in the constant presence of tested chemicals. The slopes of fluorescence increase were compared to the slope obtained for the control sample and the results were expressed as % of calpain activity detected in control cells.
Single cell measurements of cytosolic calcium levels
Cells grown on coverslips were incubated for 1 h at 37°C in HBSS-HEPES (137 mM NaCl, 0.4 mM Na 2 HPO 4 , 5.4 mM KCl, 0.4 mM KH 2 PO 4 , 1.8 mM CaCl 2 , 0.8 mM MgSO 4 and 10 mM HEPES, pH 7.4) containing 5.5 mM glucose, 5 µM fluo-3-acetoxymethyl ester and 0.025% pluronic-127. The cells were then washed three times with HBSS-HEPES and the coverslips were placed in an inverted fluorescent microscope (IX 70, Olympus) equipped with a xenon lamp light source with monochromator (Polychrome IV, Till Photonics GmbH) and a CCD camera (Till Imago, Till Photonics GmbH). The experiments were performed in HBSS-HEPES. The images of fluorescence intensities at 488 nm excitation and 510 nm longpass emission were recorded every 2 seconds. Changes in fluo-3 fluorescence in individual cells were analysed with Till Vision software. After background subtraction, the results were normalised against the initial fluorescence levels recorded in the analysed cell.
Respiration measurements
For determination of the respiration rate, C2C12 cells were detached by trypsinisation, suspended in DMEM containing 0.1% FBS, and oxygen consumption in the suspension was monitored with an oxygraph (Oroboros, Oxygraph-2k). For measurement of respiratory control ratios (RCR) the cells were suspended in the measurement buffer (120 mM KCl, 5 mM KH 2 PO 4 , 0.5 mM MgCl 2 , 10 mM HEPES and 5 mM EGTA, pH 7.3) and permeabilised with 40 µg/ml of digitonin. Oxygen consumption was determined in the presence of 10 mM glutamate and 5 mM malate alone (state 2) and after an addition of 1 mM ADP (state 3). RCR was calculated as state 3/state 2 respiration rate.
Measurements of calcium uptake by isolated sarcoplasmic reticulum
Sarcoplasmic reticulum from rat skeletal muscle was isolated as described before [28] with slight modifications. Briefly, back and leg muscles from Wistar rat were homogenized (homogenization buffer: 100 mM NaCl, 5 mM imidazole, 0.1 mM PMSF, pH 7.4) and the debris was removed by two centrifugations at 4,000 x g for 20 min. The supernatant was centrifuged at 110,000 x g for 60 min, and the resulting pellet was further fractionated on a sucrose (w/w) step gradient (45%, 38%, 34%, 32%, 27% sucrose, centrifugation at 110,000 x g for 3 h). The fractions between 32%/34% (Ca 2+ ATP-ase (SERCA) rich L-SR fraction) and between 38%/45% (H-SR fraction with lower content of SERCA pumps) were collected, diluted with 10 mM HEPES-Tris (pH 7.4), 100 mM NaCl, 0.1 mM PMSF and sedimented for 1 h at 125,000 x g. The pellets were resuspended in storage buffer (10 mM HEPES-Tris, 100 mM NaCl, 250 mM sucrose, 0.1 mM PMSF), aliquoted and stored at -70ºC. The fluorimetric measurements of Ca 2+ uptake were performed with the fura-2 fluorescent probe at excitation waveleghts 340 nm and 380 nm, and emmission wavelenght 510 nm. Calcium concentration in the measurement medium is reflected by ratio of 340 nm to 380 nm fluorescence. The measurement solution (pH 7.1) consisted of 100 mM KCl, 100 mM sucrose, 20 mM HEPES, 2 mM MgCl 2 , 2 mM NaN 3 , 5 mM potassium oxalate (K 2 C 2 O 4 ), 2 µM fura-2 and SR (5 µg protein/ml of L-SR or 7.5 µg protein/ml of H-SR). At the beginning of the measurement, an excess of ATP was added, to enable calcium uptake by the SERCA pump.
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The velocity of Ca 2+ uptake was observed after addition of 10 µM CaCl 2 . At the end of each trace 0.1 mM MnCl 2 was added, to determine the level of backround fluorescence and background correction was performed.
Statistical analysis
Statistical significance of the results was checked with two-sided Student's t-test (measurements of respiration and cytosolic calcium levels) or paired two-sided Student's t-test (cell injury and calpain activity measurements).
Results
Cytoprotective properties of BMS-191095 and calpain inhibitor PD 150606 in injured C2C12 cells
We tested the cytoprotective potential of the mitoK ATP channel opener BMS-191095 in C2C12 cells under two different stress conditions: oxidative stress induced by H 2 O 2 treatment and disruption of calcium homeostasis caused by calcium ionophore A23187. BMS-191095 was administered 10 minutes before the addition of the damaging agents (H 2 O 2 or A23187) and was present throughout the incubation time (6 h). The level of cellular damage was determined with two independent assays: the LDH release test, which measures the loss of cell membrane integrity, and the MTT reduction assay, which estimates the number of viable cells by measuring the activity of mitochondrial dehydrogenases.
Cytoprotection by BMS-191095 was not observed when cellular damage was induced by H 2 O 2 (Fig. 1A) . In contrast, both tests demonstrated a decrease in A23187-induced injury in the presence of BMS-191095 (Fig. 1) . However, the cytoprotective effect of this potassium channel opener was not reversed by 500 µM 5-hydroxydecanoic acid, an inhibitor of mitoK ATP channel (Fig. 2) . DMSO alone did not have any protective effects in the applied model. The cytoprotective effect was very strongly pronounced in presence of 30 µM BMS-191095. Therefore such concentration was applied in further experiments, despite the fact that 30 µM BMS-191095 alone induced a mild decrease in C2C12 cells viability.
To determine which mechanisms are crucial for cell death observed upon A23187 treatment, we investigated whether A23187-induced cell injury could be limited by the caspase inhibitor Z-vad-FMK, the calpain inhibitor PD 150606 or by cyclosporin A, an inhibitor of mitochondrial permeability transition. As revealed by the LDHrelease test, only the calpain inhibitor PD 150606 was protective under the applied conditions (Fig. 3A) . The rescue effects of PD 150606 were confirmed by the MTT reduction assay (Fig. 3B) . 
Influence of BMS-191095 and PD 150606 on calpain activation by A23187
To verify the dependence of cell survival on calcium ionophore-induced calpain activation, we measured calpain activity in C2C12 cells treated with A23187 alone or in combination with BMS-191095 or PD 150606. As shown in Fig. 4 , a strong increase in calpain activity was visible after 2 h of A23187 treatment. This increase was markedly limited by the presence of 100 µM PD 150606 or 30 µM BMS-191095, which correlated with the observed protection against cell injury. However, 10 µM BMS-191095, which already demonstrated mild cytoprotective properties, failed to decrease calpain activity. This shows that prevention of calpain activation may be an important, but not the only, mechanism underlying the protective effects of BMS-191095 observed in this model.
The fluorimetric measurements of short-term effects of the tested substances on calpain activity revealed that 15 minutes of preincubation with BMS-191095 did not influence calpain activity in C2C12 cells in contrast to PD 150606, which reduced the activity by approximately 50% (Fig. 5B) . Also, no effect of BMS-191095 on the activity of purified µ-calpain was detected (Fig. 5A) .
Modulation of A23187-induced calcium transients by BMS-191095
Since activation of calpains by A23187 is mediated by calcium ions, we tested whether the influence of BMS-191095 on the activity of these enzymes is related to the modulation of intracellular calcium levels. Fluo-3 measurements revealed that the addition of 1 µM A23187 caused a transient elevation in cytosolic calcium levels in C2C12 myoblasts, which in individual cells ranged between 3-and 7-fold as compared to initial levels (Fig.  6A, first panel) . Such an increase was observed regardless of extracellular Ca 2+ concentration (measurement media containing 1.8 mM or 0 mM calcium were used, 5A, third panel) . On the other hand, the A23187-induced cytosolic calcium increase was strongly decreased or completely prevented by the depletion of intracellular calcium stores with thapsigargin, an inhibitor of SERCA (sarco/endoplasmic reticulum Ca 2+ ATP-ase) pumps (Fig. 6A, fourth panel) . This shows that in C2C12 cells, A23187 increases cytosolic calcium levels mainly by releasing calcium ions from intracellular stores. Also, if administred after A23187, thapsigargin did not lead to any further increase in cytosolic calcium (data not shown), indicating that calcium removal from the reticulum by A23187 was very efficient.
After an initial increase caused by A23187 administration, cytosolic calcium levels were declining quite quickly. However, in most of analysed cells initial calcium concentrations were not reached even 10 minutes after A23187 addition. In contrast, when the cells were pretreated with 30 µM BMS-191095, the drop in cytosolic calcium levels was markedly faster and more efficient (Fig. 6C) , despite the fact that the initial peak did not differ significantly from the one observed in control cells (Fig. 6B and Fig. 6A, second panel) . The influence of the potassium channel opener itself on cytosolic Ca 2+ levels was either very weak or not detectable (data not shown). 
Influence of BMS-191095 and A23187 on oxygen consumption rates in C2C12 myoblasts
Since mitochondria have been proposed to be the target of BMS-19095 action, we investigated the effect of the drug on respiration rates in C2C12 myoblasts. In presence of the drug, up to a 2-fold increase in oxygen consumption was observed (Fig. 7A) . 30 µM BMS-191095 stimulated respiration by 1.6-fold (with ± 0.22 SD). This stimulation was not affected by the presence of 500 µM 5-HD (Fig 7B, C) .
To evaluate the extent of mitochondrial damage in A23187-treated C2C12 cells, we measured respiratory control ratios (RCR) after 6 h of treatment with the tested substances. The RCRs were determined in digitoninpermeabilised cells with glutamate + malate as respiratory substrates. Treatment with 1 µM A23187 led to a decrease in RCR (Fig. 8B ) due to reduced state 3 respiration rates (Fig. 8A) , indicating that A23187 treatment induced mitochondrial damage. Co-administration of 30 µM BMS-191095 did not prevent mitochondrial injury measured as described above.
Influence of BMS-191095 on calcium uptake by isolated sarcoplasmic reticulum
Improved efficacy of calcium removal from the cytosol can result from faster extrusion of Ca 2+ to the extracellular environment or from stimulation of calcium uptake by endoplasmic reticulum. The measurements per- formed with the use of isolated sarcoplasmic reticulum revealed, that BMS-191095 not only did not improve but even mildly decreased the speed of calcium uptake by the SR (Fig. 9) . Similar results were obtained for both heavy (H-SR) and light (L-SR) fractions of skeletal muscle sarcoplasmic reticulum. Thus, such influence of BMS-191095 on sarcoplasmic reticulum is not likely to contribute to the observed cytoprotective action.
Discussion
Potassium channel openers are known for their beneficial effects on cell survival in different stress conditions [8] . BMS-191095 was demonstrated to decrease cellular damage caused by ischemia-reperfusion [22] [23] [24] 29] , glutamate excitotoxicity and oxygen-glucose deprivation [30] . In such models, cell injury is a consequence of different pathological processes including elevation of cytosolic calcium levels, increased generation of reactive oxygen species and ATP depletion (for review see: [31] ).
In our study, cell death was induced by treatment of C2C12 myoblasts with H 2 O 2 or calcium ionophore A23187. Both models of cell injury are often used to mimic the events responsible for cellular damage during ischemia-reperfusion [32] [33] [34] [35] . Hydrogen peroxide acts primarily by causing oxidative damage to proteins, lipids and DNA, while A23187 increases intracellular calcium levels by inducing calcium influx from the extracellular environment and calcium release from intracellular stores [36] [37] [38] . In our experiments, BMS-191095 visibly increased cellular survival when the calcium ionophore A23187 was used as the damaging agent. Concentrations of BMS-191095 required to decrease ionophoreinduced cell injury (10-30 µM) were comparable to the concentrations used in other studies, in which the drug was shown to protect neuronal cultures against glutamate excitotoxicity and oxygen-glucose deprivation [30] .
Most studies on the cytoprotective action of potassium channel openers have been performed with diazoxide. Many reports have shown that during stress conditions such as hypoxia-reoxygenation, cardioplegia or treatment with oxidants, diazoxide-mediated protection is accompanied by decrease in mitochondrial damage [39] [40] [41] [42] [43] . Diazoxide was shown to preserve mitochondrial structure, respiratory rates and ATP synthesis levels, to decrease ROS generation and to prevent mitochondrial calcium overload. To investigate whether the cytoprotective effects of BMS-191095 observed in C2C12 cells were related to modulation of mitochondrial function, we performed respiration measurements. At concentrations leading to cytoprotective effects, BMS-191095 visibly increased the respiration rate in C2C12 myoblasts. Similar effect was previously reported for other potassium channel openers such as diazoxide and pinacidil [11, 44] . This result indicates that in C2C12 cells mitochondria are a target of the drug's action.
However, in our experiments BMS-191095 failed to improve mitochondrial function after A23187 treatment, and mitochondrial damage was evidenced by a decrease in state 3 respiration rate. A decrease in state 3 respiration caused by A23187 was also reported for isolated rat liver mitochondria [45] . In that experiments the decrease was strongly diminished by presence of 2 mM Mg 2+ in the incubation medium. This indicated that the decrease in state 3 respiration could result from A23187-mediated Mg concentration is estimated to be in the range of 0.5-1 mM [46] . Thus, it is not clear how much the A23187-mediated magnesium flux can contribute to the observed changes in respiration rate, besides the Ca 2+ mediated mitochodnrial damage. The main conclusion however is that in C2C12 cells potassium channel opener BMS-191095 promoted cellular survival despite impaired mitochondrial function.
Moreover, the cytoprotective effect of BMS-191095 could not be reversed by 5-HD, an inhibitor of mitoK ATP channel. This questions the involvement of mitochondrial potassium channels in BMS-191095-mediated cytoprotection in C2C12 cells. It also stays in opposition to what was reported in several studies performed on ischemia-reperfusion models [22, 47, 48] , where beneficial effects of this opener were abolished by 5-HD co-administration. On the other hand, 5-HD failed to prevent the BMS-191095-mediated neuroprotection in neuronal cultures under the conditions of oxygen-glucose deprivation or glutamate excitotoxicity [31] . Also in the study by Ahmad et al. [48] performed on heart muscle, cytosolic Akt phosphorylation observed upon BMS-191095 treatment was not 5-HD sensitive, while the openermediated cytoprotection was effectively abolished by this inhibitor. Such results suggest that BMS-191095 may have some channel-unrelated activities contributing to its protective properties. It is also not excluded that the efficacy of 5-HD-mediated mitoK ATP inhibition is tissuedependent. 5-HD can be metabolized to its CoA derivative and then enter the β-oxidation pathway [19] , so it is not clear if the inhibition is mediated by 5-HD itself or by one of its metabolites. Thus the efficacy of the inhibition may depend on cell type and metabolic state.
The channel-unrelated effects of the mitoK ATP opener diazoxide, such as succinate dehydrogenase inhibition and protonophoric properties, are well documented [17, 19, 20, 49] . In comparison to diazoxide, BMS-191095 is considered to be much more selective mitoK ATP opener [26] , however it was so far much less intensively studied than diazoxide and its off-target effects could have been not identified yet.
To identify the potential site of action of BMS-191095 responsible for observed cytoprotection, we initially tried to determine the events that are crucial for the induction of cell death in the model applied in our study. A23187-induced cell death can result from the activation of calcium-dependent proteolytic enzymes such as calpains [50, 51] , as well as from the opening of mitochondrial permeability transition pore (PTP), mitochondrial swelling and release of caspase-activating molecules from the mitochondrial intermembrane space [36, 52, 53] . To determine which mechanism is predominant in C2C12 cells, we checked the sensitivity of A23187-induced cell injury to inhibitors of calpains (PD 150606), caspases (Z-vad-FMK) and PTP (CsA). Our results show that A23187-induced injury in C2C12 myoblasts can be limited by preventing calpain activation, but not by inhibition of caspases or PTP. Calpain activity measurements confirmed that concentrations of PD 150606 which demonstrated cytoprotective effects also visibly decreased calpain activity. In contrast to PD 150606, which is a direct inhibitor of calpain [54] , BMS-191095 seems to prevent calpain activation indirectly, as it did not interfere with the activity of isolated calpain. One possible mechanism of BMS-191095 action is the limitation of A23187-induced increase in cytosolic calcium levels.
In C2C12 cells, the ionophore-induced elevation in cytosolic calcium had two phases: first, a transient but strong increase in Ca 2+ levels resulting from the release of calcium from the endoplasmic reticulum, and second, a phase of mild Ca 2+ elevation lasting for the next several minutes. The second phase seems to be related to calcium influx from the extracellular environment, as it was absent in calcium-free medium. Similar, short and ER-dependent elevation in cytosolic calcium upon addition of A23187 was reported in MH1C1 hepatoma cells [53] . The other literature data show however, that the kinetics of A23187-induced Ca 2+ influx into the cytosol may vary, dependently on the type of the cells and on the applied ionophore concentrations [55] [56] [57] [58] . For example, strong differences have been observed between poorly and highly metastatic melanoma cells [56] . The differences include: (i) the duration and the extent of the elevation in cytosolic Ca extrusion from the cell, and that the second process can lead to a decrease in overall intracellular Ca 2+ content, probably due to calcium-depletion of the ER [59, 60] .
In A23187-treated C2C12 cells, BMS-191095 visibly affected the second, plasma membrane-dependent phase of cytosolic calcium elevation, indicating that the action of this potassium channel opener is related to an inhibition of Ca 2+ influx from the extracellular environment rather than to an effect on Ca 2+ release from intracellular stores. Measurements of calcium uptake by isolated sarcoplasmic reticulum indicated, that the SR-mediated removal of Ca 2+ from the cytosol can even be slower in presence of BMS-191095 than in the absence of the drug.
Improved intracellular calcium handling was previously observed in the presence of diazoxide in a study performed on N2A neuroblastoma cells [61] . In that study, calcium influx into the cytosol was induced by purinergic stimulation, and the restoration of Ca 2+ levels to initial values was faster in presence of diazoxide. However, similar to our study, a potential link between mitochondrial potassium channel activation and calcium fluxes was not evident.
In conclusion, as depicted in Fig. 10 , our study confirms the cytoprotective properties of the potassium channel opener BMS-191095 in C2C12 cells. This action can be explained by the beneficial effects of the drug on the maintenance of intracellular calcium homeostasis under stress conditions. Whereas potassium channel opener-mediated protection was accompanied by a decrease in the proteolytic activity of calpains, the drug failed to prevent mitochondrial damage. The mechanism responsible for the observed effects of BMS-191095 on intracellular calcium levels remains unresolved and additional actions on non-mitochondrial targets cannot be excluded.
